Rebecca Knutsen is an experienced freelance writer, editor and proofreader. Please visit my blog: www.restorationwriter.com
One Way CROs Can Outshine Their Competition
Imagine you’ve hired a contractor to renovate your kitchen and a curtain is hung on the threshold, completely hindering your ability to see the project. You’re told that the curtain will be opened once a month so you may note progress. For the rest of each month, you’re left wondering whether any work is being done, if the project has hit snags, and if you approve of the project’s direction. I can think of few individuals who would stand for this type of arrangement and yet, until quite recently, that’s the way many CRO-sponsor relationships have functioned. (ghostwriting for ERT)
The Quickest Way to Save $1 Million
While we’ve all heard that developing a new drug costs more than $2 billion, the average cost of a Phase 3 clinical trial (across all therapeutic areas) is roughly $21 million over the course of about two years. (ghostwriting for ERT)
Orphan drugs face criticism on prices — and from patients - Medical ...
Orphan drugs often spell big profits for manufacturers, and unmet medical needs mean many camps are clamoring to quickly shuttle products to market.
Roche gears up to enter loaded hemophilia A drug market - Medical Marketing and Media
Roche gears up to enter loaded hemophilia A drug ma...
When it comes to PCSK9s, payers resisted — and sales flopped ...
A handful of anticipated branded products that gained FDA approval in the generics-dominated cardiovascular disease space have garnered barely audible post-launch applause. These treatments, both novel ones and me-toos, are being met with payer resistance, prescriber uncertainty, and pricing problems.
For statin-intolerant patients, what's next? - Medical Marketing and Media
Despite their blockbuster status and distinction as the world's most widely prescribed class of drugs, statins may not be the best option for all patients with elevated low density lipoprotein (LDL) cholesterol levels.
The 2017 pipeline report: What to know about next year's launches ...
The crop of late-stage biopharmaceutical agents angling for an FDA stamp of approval may find itself in one of the most challenging commercial climates in decades.
Plugging Profit Leaks
Even one leak—while seemingly small—can have damaging effects on a company’s financial health. Oncology practices are no different. (ghostwriting)
pharmaforum: Information management needs proper governance
Companies must strike the right balance in data governance and reflect its importance through well-trained data stewards. (ghostwriting)
Nexxus Healthcare and Marketing Blog
If the field of healthcare analytics had an elevator pitch, it would read something along the lines of: Data crunching has the power to add value to patient care. (ghostwriting for IMS Health)
Master the Perfect Lawn
Home Remodeling Magazine - Home Remodeling Magazine...
Cancer Care in the Crosshairs
AmerisourceBergen: Experts address the impact of impending Medicare Part B policy changes (ghostwriting).
Nexxus Blog - The World of Informed Marketers
IMS Health Gathers Panel of Life Sciences Experts to Discuss the Ripple Effects of Transforming Technology (marketing writing for IMS Health)
Using Data to Unlock the Patient Experience
Breaking down big data. (Ghostwriting for AmerisourceBergen)